Diagnostic and Interventional Cardiology Editor Dave Fornell shows some of the most innovative new technology displayed ...
May 22, 2012 - As the picture archiving and communication systems (PACS) market has developed over the last decade, the variety of images, formats and procedures available in digital form in departmental silos has proliferated. Increasingly, healthcare providers are implementing central platforms to consolidate storage, thereby reducing PACS data migration costs and enabing better data mining and data sharing across departments.
May 21, 2012 -- Boston Scientific Corp. announces results from the REPRISE I feasibility trial, which evaluated the acute safety of the Lotus Aortic Valve System in patients with severe aortic valve disease. The Lotus Aortic Valve System is the first transcatheter aortic valve replacement (TAVR) device of its kind that is designed to minimize aortic regurgitation (leaking) and is both fully repositionable and retrievable prior to release. Data presented at the annual EuroPCR Scientific Program in Paris demonstrated successful deployment of the valve in all patients with virtually no paravalvular regurgitation after valve placement or at discharge.
Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...
May 15, 2012 –– As EuroPCR 2012 gets underway, Medtronic Inc.announced that the Resolute Integrity Coronary Stent System has received European regulatory approval for several new indications, making it the drug-eluting stent (DES) with the broadest range of approved indications in Europe.
May 21, 2012 -- St. Jude Medical Inc. announced that data from the FAME II trial demonstrated a significant difference in the need for urgent revascularization when Fractional Flow Reserve (FFR)-guided assessment was used to direct treatment in patients with stable coronary artery disease. These highly statistically significant results validate the profound role that FFR-guided therapy has in improving patient outcomes. The preliminary data were presented at a late breaking trial session at EuroPCR.
May 21, 2012 — Minnetronix announced the exclusive licensing rights of Penn State Research Foundation’s wireless energy transmission technology to power circulatory assist devices in the treatment of congestive heart failure. Wireless energy transmission technology enables therapies for congestive heart failure, such as left ventricular assist devices (LVAD), to become fully implantable. Penn State is one of only two organizations in the world to have developed and deployed such a system clinically.
Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...
May 18, 2012 -- St. Jude Medical Inc., a global medical device company, announced that preliminary data demonstrated the company’s EnligHTN renal denervation system was safe and effective for the treatment of resistant hypertension. The study demonstrated that on average patients with resistant hypertension experience a systolic blood pressure reduction of 28 points after 30 days.
May 18, 2012 — AliveCor, the developer of a breakthrough mobile electrocardiogram (ECG) recorder, announced results from a study that demonstrated the accuracy of the company’s iPhone-based device, by comparing its Lead I to Lead I from a conventional 12-lead ECG. The study found that the iPhone-based event recorder is an accurate clinical tool for ECG assessment and could prove to be a new tool for allowing immediate recording and analysis of an ECG rhythm.
May 18, 2012 -- A study conducted at Scripps Health has found that a novel new heart monitoring device helped emergency room patients avoid unnecessary follow-up care. Scripps Health electrophysiologist Steven Higgins, M.D., presented findings of the study titled, "Prevalence of Arrhythmias in Emergency Department Patients Discharged Using a Novel Ambulatory Cardiac Monitor,"at the Heart Rhythm Society's 33rd Annual Scientific Sessions in Boston.
When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...
May 18, 2012 - New research from the University at Buffalo suggests that cardiologists may have a new way to identify patients who are at the highest risk of sudden cardiac arrest, and the most likely to benefit from receiving an implantable cardiac defibrillator (ICD).
The U.S. Food and Drug Administration (FDA) today approved generic versions of the blood-thinning drug Plavix (clopidogrel), which is expected to have a major impact on the cost to treat patients at risk of heart attack and stroke.
May 17, 2012 — Boston Scientific Corp. announces CE mark and European market launch of the Innova Self-Expanding Bare-Metal Stent System, which is designed to treat peripheral vascular lesions in arteries above the knee, specifically the superficial femoral artery (SFA) and proximal popliteal artery (PPA). The company plans to launch the product immediately in Europe and other CE mark countries.
Change Healthcare Cardiology Hemodynamics is an integrated hemodynamic monitoring system for monitoring vital signs and ...
May 17, 2012 - Philips Healthcare announced the availability of CardioCare Wireless Arrhythmia Services, the latest addition to the company’s remote diagnostic arrhythmia and remote patient monitoring portfolio. This new service, available only in the United States, is designed to streamline the complex process of remotely monitoring cardiac patients and capture critical information sooner.
Heart Rhythm Society (HRS) President-Elect Hugh Calkins, M.D., FACC, director, cardiac arrhythmia services and EP lab ...
A new electromapping technique can better visualize the rotor (similar to the eye of a hurricane) around which atrial fibrillation electrical activity rotates. Using this map, the electrophysiologist can position an ablation catheter on the rotor center and see immediately results of the treatment. By using this targeted technique, in some cases a single ablation can terminate the AFib.